Abstract
Objective: to evaluate the efficiency of basic therapy for rheumatoid arthritis (RA) depending on the time of its start and the choice of a starting regimen. Subjects and methods. The study included 258 patients with verified RA, who were divided into groups by the time of basic therapy initiation. All the patients were estimated for changes in the articular syndrome (Ritchie articular index, the number of painful joints, that of inflamed joints, pain and total disease activity assessment by the visual analogue scale, morning stiffness in minutes, and the number of erosions by hand and foot X-ray films). Therapeutic effectiveness was evaluated by the EULAR criteria on the basis of DAS 4 changes and the number of erosions. Results. The study group showed significant clinical and laboratory improvements at the early start of basic therapy as compared with the controls. Assessment using the EURLAR criteria indicated better short-term results in leflunomide-treated patients; overall, a greater percentage of improvements were noted in the study group than in the control one. The study group exhibited a total significantly less increase in the number of erosions as did subgroups with different basic therapy options, but not the sulfasalazine subgroup. Conclusion. Basic therapy initiated at the time of diagnosis of RA permits disease activity and progression to be more effectively controlled than delayed therapy
Highlights
The study included 258 patients with verified rheumatoid arthritis (RA), who were divided into groups by the time of basic therapy initiation
Assessment using the EURLAR criteria indicated better short-term results in leflunomide-treated patients; overall, a greater percentage of improvements were noted in the study group than in the control one
Исходные параметры суставного синсульфасалазин превосходил отсроченную терапию базисных противовоспалительных препаратов (БПВП) в дрома: суставной индекс Ричи (СИ) — 16,89±9,69, ЧБС — 19,6±9,79, число припухших суставов (ЧПС) — 10,4±8,32, контрольной группе: через 6 мес хороший результат достиг- УС — 232,22±167,76 мин, общее состояние здоровья (ОСЗ) по ВАШ — 65,89±16,64 мм, вынут в 14,3% случаев против 8%, а удовлетворительный — в раженность боли по ВАШ — 71,25±15,39 мм
Summary
Цель исследования — оценить эффективность базисной терапии ревматоидного артрита (РА) в зависимости от сроков ее начала и выбора стартового режима. В исследование включены 258 больных достоверным РА, которые были разделены на группы в зависимости от сроков начала базисной терапии. Отмечено достоверное улучшение клинических и лабораторных параметров в основной группе при раннем начале базисной терапии по сравнению с таковыми в контроле. При оценке по критериям EULAR лучшие ближайшие результаты получены у больных, леченных лефлуномидом, а в целом больший процент улучшений отмечен в основной группе в отличие от группы контроля. The study included 258 patients with verified RA, who were divided into groups by the time of basic therapy initiation. Assessment using the EURLAR criteria indicated better short-term results in leflunomide-treated patients; overall, a greater percentage of improvements were noted in the study group than in the control one. Динамикаиндекса DA S 4 порекомендациямEULAR нии, а наиболее высокая скорость нарастания рентгенологических изменений в суставах наблюдается именно на Итоговое значение
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
